Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 18,300 matching trials from the live ClinicalTrials.gov search.
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246

NCT00907803
Conditions
Orthopoxviral Disease
Interventions
ST-246 400 mg, ST-246 600 mg, Placebo
Drug
Lead sponsor
SIGA Technologies
Industry
Eligibility
18 Years to 75 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
Santa Ana, California • Orlando, Florida • Honolulu, Hawaii
Conditions
Osteoarthritis of the Knee
Interventions
ketoprofen Patch, Placebo Patch
Drug · Other
Lead sponsor
Hisamitsu Pharmaceutical Co., Inc.
Industry
Eligibility
45 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
36
States / cities
Birmingham, Alabama • Chandler, Arizona • Peoria, Arizona + 31 more
Conditions
Knee Osteoarthritis
Interventions
Liposomal bupivacaine, Ropivacaine, Epinephrine, Clonidine, Saline
Drug
Lead sponsor
The Hawkins Foundation
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Greenville, South Carolina
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers

NCT03565861
Conditions
Safety Issues
Interventions
Placebo, NP10679
Drug
Lead sponsor
Neurop Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Protein Blends on Muscle Protein Synthesis in Healthy Older Adults

NCT01847261
Conditions
Muscle Synthesis
Interventions
Soy Dairy Protein Blend, Positive Control (Dairy Whey Protein)
Dietary Supplement
Lead sponsor
DuPont Nutrition and Health
Industry
Eligibility
55 Years to 70 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Postural Tachycardia Syndrome
Interventions
Stellate ganglion block, Sham injection of saline, Ropivacaine, Normal saline
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Stanford, California
Conditions
Ulcerative Colitis
Interventions
SPH3127, Placebo
Drug
Lead sponsor
Shanghai Pharma Biotherapeutics USA Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
16
States / cities
Huntsville, Alabama • Los Angeles, California • Mission Hills, California + 13 more
Conditions
Hot Flushes, Menopause, Postmenopause
Interventions
Esterified Estrogens (EE) and Methyltestosterone (MT)
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
1,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
88
States / cities
Montgomery, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 69 more
Conditions
Atopic Dermatitis Eczema
Interventions
ALX-101 Gel Vehicle, ALX-101 Gel 5%
Drug
Lead sponsor
Ralexar Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Beverly Hills, California • Los Angeles, California • Aventura, Florida + 17 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of SPY002-072 in Healthy Volunteers

NCT06622070
Conditions
Healthy
Interventions
SPY002-072, Placebo
Drug · Other
Lead sponsor
Spyre Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cypress, California
Conditions
Cachexia
Interventions
GSK2881078, Placebo, Itraconazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Post-traumatic Stress Disorder
Interventions
Hydrocortisone, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
La Jolla, California
Conditions
Healthy Subjects
Interventions
E5555
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Squamous Cell Carcinoma in Situ
Interventions
STP705, Placebo Saline
Drug · Other
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Scottsdale, Arizona • Aventura, Florida • West Palm Beach, Florida + 4 more
Conditions
Alopecia, Androgenetic
Interventions
TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
North Little Rock, Arkansas • Rolling Meadows, Illinois • Plainfield, Indiana + 10 more
Conditions
Obsessive-Compulsive Disorder
Interventions
Psilocybin (0.25mg/kg), Niacin (250mg)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Not applicable Interventional Results available

Low Intensity Ultrasound Therapy for Upper Back Pain Relief

NCT02135094
Conditions
Muscle Spasm
Interventions
Active ultrasound therapy device, Placebo ultrasound therapy device
Device
Lead sponsor
ZetrOZ, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Trumbull, Connecticut
Conditions
Atopic Dermatitis
Interventions
Placebo, ZPL389 3mg, ZPL389 10mg, ZPL389 30mg, ZPL389 50mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
12
States / cities
Litchfield Park, Arizona • Fountain Valley, California • San Diego, California + 7 more
Conditions
Non-erosive Reflux Disease
Interventions
BLI5100, Placebo
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
788 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
112
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 92 more
Conditions
HIV Infections, Pneumococcal Infections
Interventions
Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 6 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
31
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 21 more
Conditions
End Stage Renal Disease
Interventions
GHRP-1/AG 70 mg depot in ESRD, Placebo
Drug · Other
Lead sponsor
QLT Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
New Orleans, Louisiana • Rochester, Minnesota
Completed Phase 2 Interventional Accepts healthy volunteers

Recombinant CMV gB Vaccine in Postpartum Women

NCT00125502
Conditions
Cytomegalovirus Infections
Interventions
CMV gB vaccine, MF59 adjuvant, Placebo
Biological · Drug
Lead sponsor
Robert Pass, MD
Other
Eligibility
14 Years to 40 Years · Female only
Enrollment
464 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2010
U.S. locations
2
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama
Conditions
Meningococcal Meningitis, Meningococcal Infections
Interventions
Test Vaccine, US Licensed Vaccine
Biological
Lead sponsor
JN-International Medical Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
525 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
3
States / cities
Greenbelt, Maryland • Pasadena, Maryland • Towson, Maryland
Conditions
COVID-19
Interventions
PF-07321332, Ritonavir, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,091 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
73
States / cities
Pelham, Alabama • Mesa, Arizona • Tucson, Arizona + 46 more